BBOT News

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Biobot Analytics Selected by White House Office of National Drug Control Policy to Provide Nationwide Wastewater Intelligence on Substance Use Trends

BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs

BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference

BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)

BBOT to Participate in Upcoming December Investor Healthcare Conferences

BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

BBOT to Participate in the Jefferies Global Healthcare Conference in London

BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)